Prospective analysis of serum prolactin levels, clinical symptomatology and sexual functions in patients with schizophrenia switched to paliperidone palmitate 3-monthly from paliperidone palmitate 1-monthly: Preliminary findings of the first 3 months

IF 1.8 4区医学 Q3 CLINICAL NEUROLOGY

Human Psychopharmacology: Clinical and Experimental Pub Date : 2021-11-17 DOI:10.1002/hup.2827

Ersin Hatice Karslioğlu, Zeynep Kolcu, Nisa İrem Karslioğlu, Ali Çayköylü

{"title":"Prospective analysis of serum prolactin levels, clinical symptomatology and sexual functions in patients with schizophrenia switched to paliperidone palmitate 3-monthly from paliperidone palmitate 1-monthly: Preliminary findings of the first 3 months","authors":"Ersin Hatice Karslioğlu, Zeynep Kolcu, Nisa İrem Karslioğlu, Ali Çayköylü","doi":"10.1002/hup.2827","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Long-acting injectable (LAI) antipsychotics were developed to improve adherence to schizophrenia treatment. Paliperidone palmitate (PP) has two LAI forms: Monthly (PP1M) and three-monthly (PP3M). PP3M shows less difference in Peak-to-Trough drug concentration levels. This could be related to a lower incidence of hyperprolactinemia, which may negatively affect adherence. We aimed to compare prolactin levels and investigate relationships between prolactin levels, symptomatology and sexual function in patients with schizophrenia after switching from PP1M to PP3M.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Twenty-five patients were enrolled. The sociodemographic data form, the Positive and Negative Syndromes Scale (PANSS) and the Arizona Sexual Experience Scale (ASEX) were used. Morning blood samples were drawn to determine prolactin levels.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Prolactin level (<i>p</i> < 0.001), the total score and arousal sub-score of ASEX (respectively; <i>p</i> = 0.015, <i>p</i> = 0.020) and the total score and positive scale of PANSS (respectively; <i>p</i> = 0.017, <i>p</i> = 0.021) were decreased on the 90th day (±15 days).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>After switching to PP3M, the decreases in prolactin levels and potentially related sexual side effects was statistically significant. There may be a difference between two formulations of the same drug in terms of side effects, and there is a need for prospective follow-up studies with larger samples.</p>\n </section>\n </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"37 3","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2021-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.2827","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Objective

Long-acting injectable (LAI) antipsychotics were developed to improve adherence to schizophrenia treatment. Paliperidone palmitate (PP) has two LAI forms: Monthly (PP1M) and three-monthly (PP3M). PP3M shows less difference in Peak-to-Trough drug concentration levels. This could be related to a lower incidence of hyperprolactinemia, which may negatively affect adherence. We aimed to compare prolactin levels and investigate relationships between prolactin levels, symptomatology and sexual function in patients with schizophrenia after switching from PP1M to PP3M.

Methods

Twenty-five patients were enrolled. The sociodemographic data form, the Positive and Negative Syndromes Scale (PANSS) and the Arizona Sexual Experience Scale (ASEX) were used. Morning blood samples were drawn to determine prolactin levels.

Results

Prolactin level (p < 0.001), the total score and arousal sub-score of ASEX (respectively; p = 0.015, p = 0.020) and the total score and positive scale of PANSS (respectively; p = 0.017, p = 0.021) were decreased on the 90th day (±15 days).

Conclusions

After switching to PP3M, the decreases in prolactin levels and potentially related sexual side effects was statistically significant. There may be a difference between two formulations of the same drug in terms of side effects, and there is a need for prospective follow-up studies with larger samples.

查看原文本刊更多论文

从棕榈酸帕利哌酮1个月改用棕榈酸帕利哌酮3个月的精神分裂症患者血清催乳素水平、临床症状和性功能的前瞻性分析:前3个月的初步结果

目的研制长效注射抗精神病药物，提高精神分裂症治疗的依从性。棕榈酸帕利哌酮(PP)有两种LAI形式:每月(PP1M)和三个月(PP3M)。PP3M在峰谷药物浓度水平上差异较小。这可能与高泌乳素血症发生率较低有关，这可能对依从性产生负面影响。我们的目的是比较催乳素水平，并研究精神分裂症患者从PP1M转为PP3M后催乳素水平、症状和性功能之间的关系。方法入选25例患者。采用社会人口学数据表、阳性和阴性症状量表(PANSS)和亚利桑那性经验量表(ASEX)。早上抽取血样以测定催乳素水平。结果催乳素水平(p <0.001)， ASEX总分和唤醒分值分别为;p = 0.015, p = 0.020)， PANSS总分和阳性量表分别为;P = 0.017, P = 0.021)在第90天(±15天)下降。结论改用PP3M后，催乳素水平下降及相关的性副作用均有统计学意义。同一药物的两种剂型在副作用方面可能存在差异，因此需要对更大样本进行前瞻性随访研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Psychopharmacology: Clinical and Experimental 医学-精神病学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal: -All aspects of clinical psychopharmacology- Efficacy and safety studies of novel and standard psychotropic drugs- Studies of the adverse effects of psychotropic drugs- Effects of psychotropic drugs on normal physiological processes- Geriatric and paediatric psychopharmacology- Ethical and psychosocial aspects of drug use and misuse- Psychopharmacological aspects of sleep and chronobiology- Neuroimaging and psychoactive drugs- Phytopharmacology and psychoactive substances- Drug treatment of neurological disorders- Mechanisms of action of psychotropic drugs- Ethnopsychopharmacology- Pharmacogenetic aspects of mental illness and drug response- Psychometrics: psychopharmacological methods and experimental design